Exelixis and Sairopa B.V. announced that the FDA has cleared Sairopa’s investigational new drug, or IND, application to evaluate the safety and pharmacokinetics of ADU-1805 in adults with advanced solid tumors. As a monoclonal antibody active against all human alleles of SIRPa, ADU-1805 has the potential to address a broader patient population than other SIRPa-directed therapies.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EXEL:
- Exelixis sees FY23 revene $1.775B-$1.875B, consensus $1.84B
- Exelixis reports Q4 EPS (3c), consensus (12c)
- Exelixis options imply 3.8% move in share price post-earnings
- Credit Suisse Says These 2 Stocks Could Surge Over 30% From Current Levels
- Credit Suisse bullish on Exelixis, initiates with an Outperform
